Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hemlibra
Pharma
BioMarin's hemophilia gene therapy needs 3 stars to align: CEO
BioMarin's Roctavian only sold $3.5 million in 2023, as new CEO Alexander Hardy looks to the next two years to prove the gene therapy's value.
Angus Liu
Feb 23, 2024 10:15am
JPM24: Roche touts its rebound in hematology, led by Hemlibra
Jan 9, 2024 4:26pm
Roche scores again in hemophilia drug patent case against Takeda
Sep 21, 2023 11:00am
Bayer cuts 55 jobs at its rapidly growing Berkeley campus
Feb 22, 2023 10:55am
ICER endorses multimillion-dollar hemophilia gene therapies
Sep 14, 2022 11:38am
Who's at risk in the next pandemic? Regeneron, Biogen, plus more
Mar 12, 2021 11:47am
